Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034463 · ClinicalTrials.gov registry record · Phase 1
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00034463 is a Phase 1 study that has completed, run by Eli Lilly and Company.
The verdict
NCT00034463, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
Interventions
- DRUG ALIMTA
- DRUG folic acid
- DRUG multi-vitamins
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034463
The ClinicalTrials.gov registry entry for NCT00034463 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ALIMTA is the first listed.
NCT00034463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00034463 about?
NCT00034463 is a clinical study titled "ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer". This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated p...
What is the current status of trial NCT00034463?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00034463?
The interventions under investigation include: ALIMTA (DRUG), folic acid (DRUG), multi-vitamins (DRUG).
Who is sponsoring clinical trial NCT00034463?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.